8th November 2026, Sunday

TechPharus

Latest Posts

HealthTech News

  • Financial incentives nearly double quit rates among underserved people who smoke in national study
    on November 7, 2026 at 10:00 pm

    Offering financial incentives to people trying to quit smoking nearly doubled cessation rates among medically underserved adults undergoing lung cancer screening, according to a large national clinical trial involving Henry Ford Health.

  • Potential driver of severe early-onset preeclampsia identified
    on November 7, 2026 at 7:00 pm

    Severe early-onset preeclampsia has confounded doctors for more than 2,000 years. It can strike as early as 20 weeks into pregnancy, sending blood pressure soaring and putting both the mother and baby at risk.

  • Normal-looking sleep can mask memory problems, study suggests
    on November 7, 2026 at 3:40 pm

    A new mouse study that set out to test how sleep helps stabilize new memories has identified cells that may offer a genetic target for accessing circuits implicated in cognitive disorders. Researchers led by Min Xu and Wanling Peng from the Institute of Neuroscience at the Chinese Academy of Sciences focused on interneurons that gate the generation of ripples, which are brief bursts of electrical activity that are critical for memory consolidation.

  • New treatment may cure common hormonal cause of high blood pressure
    on November 7, 2026 at 2:40 pm

    A study led by Queen Mary University of London has found that a new treatment could offer a lasting cure for some people with a common hormonal cause of high blood pressure, even after they stop taking medication.

  • Heart researchers unpack neutral findings from ZEUS, an anti-inflammatory clinical trial
    on November 7, 2026 at 2:40 pm

    Like cholesterol, inflammation causally contributes to the risk of cardiovascular disease, but findings from the clinical trial ZEUS indicate that the road to targeting inflammation may be less straightforward than once thought. ZEUS, a global phase 3 clinical trial led by Mass General Brigham researcher Paul Ridker, M.D., tested a drug that targets interleukin-6 (IL-6), a downstream inflammatory molecule. IL-6 inhibitors are commonly used to treat autoimmune disorders. However, while the new drug known as ziltivekimab lowered IL-6 levels, it did not reduce cardiovascular event rates compared to placebo.